National Research Corporation

$ 18.54 4.45 %

National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.

CEO: Trent Green - https://nrchealth.com

Price objectif

-

Recommandation

-

DCF

$ 13.10

Loading data...

NRC vs S&P500

Loading data...

No data available.

Quick ratio

0.52

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

47.54

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

0.39

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

57.24 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

12.18 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

5.85

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

5.78

means it relies more on debt, which can increase financial risk.

Free cash flow per share

0.80

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

130.98 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
5 indicates moderate financial health
Altman score
3.23 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.07 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.58 indicates a moderate level of debt, which is generally acceptable but may present some risk
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.